Alzamend Neuro Inc (ALZN)

$2.15 +0.09 (4.37%)
Market Cap 6.44M
Revenue (ttm) 0.00
Net Income (ttm) -4.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 23,400
Avg Vol 125,950
Day's Range N/A - N/A
Shares Out 3.14M
Stochastic %K 38%
Beta -0.25
Analysts Sell
Price Target $42.00

Company Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-pe...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 722 6333
Address:
3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, United States
Jdog100000000
Jdog100000000 Dec. 4 at 9:13 PM
$ALZN man I’m glad I got out of this in the 5s thought I would check back in..that dark pool short fill from a 98 percent float really sealed the deal for me..
0 · Reply
AvengerTrader
AvengerTrader Dec. 4 at 8:48 PM
What is happening to ticker SNSE now?! Looks like they are going to SQUEEZE ticker SNSE up next .. SNSE is breaking out like crazy.. Are they pumping up SNSE for 300% !? Its insane what's going on in this market.. Looks like all eyes are going to SNSE now.. Watching: $JAGX $HCTI $ALZN $INTC now=
1 · Reply
topstockalerts
topstockalerts Dec. 3 at 1:53 PM
Pre Market Top Gainers PT2 $AHMA $MVLL $TARA $SMX $ALZN
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 1:02 PM
Pre Market Top Gainers PT2 $MVLL $SMX $ALZN $GSUN $AGMH
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 12:47 PM
Pre Market Top Gainers PT2 $PHVS $MVLL $ALZN $NXXT $GSUN
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 12:04 PM
Pre Market Top Gainers PT2 $MVLL $CAPR $ALZN $SMX $NXXT
0 · Reply
hiwatt
hiwatt Nov. 26 at 3:15 AM
$ALZN Just looking at the time frame on P2 A, The MDA study. It was 2 months 21 days from the time Alzn announced they had completed the clinical part of the study until they announced results. There was 65 patients in the study, half on lithium, half on AL001 and 16 on placebo mixed into these groups. You would think with just 6 people in the last clinical trial and with QMENTA using AI to oversee the trial as it progressed, it would not take that long to process the results, unless there is a backlog somewhere in the system.
1 · Reply
hiwatt
hiwatt Nov. 22 at 4:31 PM
$ALZN In doing my DD on this company, two criticisms rise to the top. First was their opening day MC of $1.5B which was overvalued considering where they were on the scientific side. Was that the workings of Todd, IDK?? They only received $14M, as a result, but had a MC of $1.15B. Just 3 months later they had lost 75% of that evaluation before they had even started P1 for AL001. Second they have a history of overpromising and underdelivering on a timely basis. Latest example, data for P2 was due in Dec, now Q1. Markets don't like delays. I'm not surprised because once I saw an interview where CEO Stephan and he was completely unaware of the stock price. As far as execution of clinical trials and getting good results, he has been spot on. So that reason, I'm riding this one out. Maybe karma will prevail in the end, now that Todd has sold over 900K of his shares.
1 · Reply
hiwatt
hiwatt Nov. 21 at 9:23 PM
$ALZN Added more today at$1.97 and I reached my limit for this stock. On clinical trials they originally estimated 1 month between primary completion and study completion, so maybe Qmenta's AI can deliver it by Christmas, good or bad. Either way, I expect some time in January to be the latest.
0 · Reply
PeteRePete
PeteRePete Nov. 21 at 7:39 PM
$ALZN I have bids 1.80s but I took a few thousand 1.96 1.97, think next week lots of these types gonna do that typical 20 to 40% fast spike, so many are so oversold now especially these low float type like this.
1 · Reply
Latest News on ALZN
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Nov 19, 2025, 8:00 AM EST - 15 days ago

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Jul 28, 2025, 8:00 AM EDT - 4 months ago

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Jul 23, 2025, 8:00 AM EDT - 4 months ago

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Jun 16, 2025, 8:00 AM EDT - 6 months ago

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 29, 2025, 8:00 AM EDT - 6 months ago

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 19, 2025, 8:00 AM EDT - 7 months ago

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 13, 2025, 8:00 AM EDT - 7 months ago

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Announces Reverse Stock Split

May 8, 2025, 8:00 AM EDT - 7 months ago

Alzamend Neuro Announces Reverse Stock Split

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

May 7, 2025, 8:00 AM EDT - 7 months ago

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Mar 25, 2025, 8:00 AM EDT - 9 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Mar 18, 2025, 8:00 AM EDT - 9 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Mar 11, 2025, 8:00 AM EDT - 9 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Mar 4, 2025, 8:10 AM EST - 9 months ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Feb 25, 2025, 8:00 AM EST - 10 months ago

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Aug 19, 2024, 9:41 AM EDT - 1 year ago

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

ABBV

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

May 7, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Apr 4, 2023, 6:30 AM EDT - 2 years ago

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

Nov 28, 2022, 6:30 AM EST - 3 years ago

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

Nov 22, 2022, 8:05 AM EST - 3 years ago

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

Nov 21, 2022, 7:27 PM EST - 3 years ago

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Nov 1, 2022, 6:30 AM EDT - 3 years ago

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Sep 22, 2022, 8:00 AM EDT - 3 years ago

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 17, 2021, 11:59 PM EST - 4 years ago

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

Dec 17, 2021, 9:54 AM EST - 4 years ago

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

Why Alzamend Neuro Stock Soared Today

Dec 14, 2021, 6:35 PM EST - 4 years ago

Why Alzamend Neuro Stock Soared Today

See Why Alzamend Neuro Stock Is Rallying On Thursday

Sep 30, 2021, 1:45 PM EDT - 4 years ago

See Why Alzamend Neuro Stock Is Rallying On Thursday

Why Alzamend Neuro Shares Are Surging Higher Today

Sep 30, 2021, 11:54 AM EDT - 4 years ago

Why Alzamend Neuro Shares Are Surging Higher Today

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Sep 30, 2021, 10:11 AM EDT - 4 years ago

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Sep 13, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Aug 4, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Jul 30, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 28, 2021, 3:07 PM EDT - 4 years ago

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Why Alzamend Neuro Stock Fell More Than 14% Today

Jul 26, 2021, 4:03 PM EDT - 4 years ago

Why Alzamend Neuro Stock Fell More Than 14% Today

Here's Why Alzamend Neuro Stock Is Shooting Higher Today

Jul 23, 2021, 12:44 PM EDT - 4 years ago

Here's Why Alzamend Neuro Stock Is Shooting Higher Today

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Jul 23, 2021, 7:20 AM EDT - 4 years ago

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Jul 23, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Jul 12, 2021, 6:00 AM EDT - 4 years ago

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Jul 1, 2021, 11:23 AM EDT - 4 years ago

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 1, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Why Alzamend Neuro Stock Popped Today

Jun 28, 2021, 3:59 PM EDT - 4 years ago

Why Alzamend Neuro Stock Popped Today

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Jun 17, 2021, 4:30 PM EDT - 4 years ago

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Jun 16, 2021, 6:30 AM EDT - 4 years ago

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Alzamend Neuro Announces Pricing of Initial Public Offering

Jun 14, 2021, 5:49 PM EDT - 4 years ago

Alzamend Neuro Announces Pricing of Initial Public Offering

Jdog100000000
Jdog100000000 Dec. 4 at 9:13 PM
$ALZN man I’m glad I got out of this in the 5s thought I would check back in..that dark pool short fill from a 98 percent float really sealed the deal for me..
0 · Reply
AvengerTrader
AvengerTrader Dec. 4 at 8:48 PM
What is happening to ticker SNSE now?! Looks like they are going to SQUEEZE ticker SNSE up next .. SNSE is breaking out like crazy.. Are they pumping up SNSE for 300% !? Its insane what's going on in this market.. Looks like all eyes are going to SNSE now.. Watching: $JAGX $HCTI $ALZN $INTC now=
1 · Reply
topstockalerts
topstockalerts Dec. 3 at 1:53 PM
Pre Market Top Gainers PT2 $AHMA $MVLL $TARA $SMX $ALZN
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 1:02 PM
Pre Market Top Gainers PT2 $MVLL $SMX $ALZN $GSUN $AGMH
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 12:47 PM
Pre Market Top Gainers PT2 $PHVS $MVLL $ALZN $NXXT $GSUN
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 12:04 PM
Pre Market Top Gainers PT2 $MVLL $CAPR $ALZN $SMX $NXXT
0 · Reply
hiwatt
hiwatt Nov. 26 at 3:15 AM
$ALZN Just looking at the time frame on P2 A, The MDA study. It was 2 months 21 days from the time Alzn announced they had completed the clinical part of the study until they announced results. There was 65 patients in the study, half on lithium, half on AL001 and 16 on placebo mixed into these groups. You would think with just 6 people in the last clinical trial and with QMENTA using AI to oversee the trial as it progressed, it would not take that long to process the results, unless there is a backlog somewhere in the system.
1 · Reply
hiwatt
hiwatt Nov. 22 at 4:31 PM
$ALZN In doing my DD on this company, two criticisms rise to the top. First was their opening day MC of $1.5B which was overvalued considering where they were on the scientific side. Was that the workings of Todd, IDK?? They only received $14M, as a result, but had a MC of $1.15B. Just 3 months later they had lost 75% of that evaluation before they had even started P1 for AL001. Second they have a history of overpromising and underdelivering on a timely basis. Latest example, data for P2 was due in Dec, now Q1. Markets don't like delays. I'm not surprised because once I saw an interview where CEO Stephan and he was completely unaware of the stock price. As far as execution of clinical trials and getting good results, he has been spot on. So that reason, I'm riding this one out. Maybe karma will prevail in the end, now that Todd has sold over 900K of his shares.
1 · Reply
hiwatt
hiwatt Nov. 21 at 9:23 PM
$ALZN Added more today at$1.97 and I reached my limit for this stock. On clinical trials they originally estimated 1 month between primary completion and study completion, so maybe Qmenta's AI can deliver it by Christmas, good or bad. Either way, I expect some time in January to be the latest.
0 · Reply
PeteRePete
PeteRePete Nov. 21 at 7:39 PM
$ALZN I have bids 1.80s but I took a few thousand 1.96 1.97, think next week lots of these types gonna do that typical 20 to 40% fast spike, so many are so oversold now especially these low float type like this.
1 · Reply
SimSimBola
SimSimBola Nov. 20 at 9:08 PM
$ALZN Todd, the dud 💩
1 · Reply
AntoineChigurh
AntoineChigurh Nov. 20 at 8:54 PM
$ALZN Todd strkes again.
0 · Reply
SimSimBola
SimSimBola Nov. 20 at 8:49 PM
$ALZN chart is showing 1.75-1.80 as a bottom. loads of drifting between now and jan 2nd. ripe for scalping.
1 · Reply
Scrood_the_Pooch
Scrood_the_Pooch Nov. 20 at 8:29 PM
$ALZN @AntoineChigurh
1 · Reply
SimSimBola
SimSimBola Nov. 20 at 7:43 PM
$ALZN ding ding ding! Welcome new 52 week low, courtesy of a stupid press release. its a gamble alright
0 · Reply
Noname66
Noname66 Nov. 20 at 6:40 PM
$ALZN Yesterday's news was death sentence for ALZN till next three months. Sorry I sold it yesterday.
0 · Reply
ipaidtoomuch
ipaidtoomuch Nov. 20 at 1:14 PM
$ALZN trying to add in this range without the algo figuring it out. I always hold a small amount of these shares less than 10k for the "what if it works angle" Strong dislike for some of the people involved but the greater good prevails for me here.
0 · Reply
SimSimBola
SimSimBola Nov. 19 at 6:10 PM
$ALZN inverted head and shoulder
0 · Reply
SimSimBola
SimSimBola Nov. 19 at 3:58 PM
$ALZN sell off. and rightfully so. first qtr 2026 can be march ...thats a loooong time in trading world
0 · Reply
SimSimBola
SimSimBola Nov. 19 at 3:57 PM
$ALZN well....
0 · Reply
SimSimBola
SimSimBola Nov. 19 at 2:44 PM
$ALZN trading like they will make a new 52 week low. this news is ripe for shorting. they basically announced nothing to see here for next 3-4 months. meanwhile, lights are kept on so burn continues.
0 · Reply
hiwatt
hiwatt Nov. 19 at 1:50 PM
$ALZN Key points to keep in mind is this not a new drug, but a drug that has been around for 154 years. The main issue has always been a toxicity, not efficacy. Even with that, it is still considered the gold standard in treatment of BP and underprescribed because of followup testing. Now with a new compound (AL001)and now the ability to prove it works (Tesla coil) with a lower dose that is not toxic, accelerated approval pathway may be in the cards. They just need to take their time and make a compelling case!!
0 · Reply